We are pleased to announce that the 15th edition of the International Workshop on Clinical Pharmacology of Tuberculosis Drugs will take place 1-2 October 2024 as a virtual meeting.
This abstract-driven workshop has been the leading annual meeting in the tuberculosis (TB) pharmacology field since 2008. The aim of the meeting is to contribute to the optimization of TB treatment by providing an independent platform for presentation and discussion of the latest scientific developments in the TB pharmacology field.
If you work in the field of TB, you are invited to join us. This includes preclinical and clinical pharmacology researchers from academia and industry; medical doctors, pharmacists and pharmacologists involved in clinical management of TB patients; laboratorians, nurses, PhD students; and representatives from regulatory or non-governmental organizations active in the TB-field.
The program consists of e-poster abstract presentations. The workshop is informal in setting and is meant to be interactive.
We look forward to seeing you virtually this October!
On behalf of the Organizing Committee,
Lectures | Speakers | Presentations | Abstracts |
DAY 1 Tuesday 1 October | |||
Session 1 Drugs: clinical and non-clinical pharmacology of TB drugs | |||
Chairs: Jerry Nedelman & Eric Nuermberger | |||
Model-informed once-daily dosing strategy for bedaquiline and delamanid in children, adolescents and adults with tuberculosis | Yu-Jou Lin | Abstract | |
Linezolid dosing and pharmacokinetics in North American patients with tuberculosis, 2019-2023 | Nicole Maranchick | Abstract | |
Pharmacogenetics and pharmacokinetics of moxifloxacin in MDR-TB patients in Indonesia: analysis for ABCB1 rs2032582 and SLCO1B1 | Nurul Annisa | Abstract | |
Delpazolid population pharmacokinetics and pharmacodynamics in patients with pulmonary tuberculosis | Isabella van der Feltz | Abstract | |
Session 2 Patient populations: pharmacological aspects of specific forms of mycobacterial diseases (TB meningitis) | |||
Chairs: Caitlin Reed & Christine Sekaggya-Wiltshire | |||
Pharmacokinetic modelling of rifampicin, isoniazid, pyrazinamide, linezolid and rifabutin in CNS tissues: a rabbit model study of tuberculosis meningitis | Noha Adbelgawad | Abstract | |
Pharmacokinetic analysis of isoniazid and dexamethasone in adults with tuberculosis meningitis | Jose Miguel Calderin Miranda | Abstract | |
Pharmacokinetics and safety/tolerability of linezolid in Indonesian TB meningitis patients | Lindsey te Brake | ||
Dynamic PET reveals compartmentalized brain and lung tissue antibiotic exposures of tuberculosis drugs | Xueyi Chen | Abstract | |
Rapporteur session | Rob Aarnoutse | ||
Session 3 Patient populations: pharmacological aspects of specific forms of mycobacterial diseases (TB in pregnancy, children, extrapulmonary TB, NTM disease) | |||
Chairs: Nicole Maranchick & Ulrika Simonsson | |||
Population pharmacokinetics of delamanid in adults treated for rifampicin-resistant tuberculosis: effect of pregnancy | Sharon Sawe | Abstract | |
Pharmacokinetics and dosing of dispersible moxifloxacin formulation in children with rifampicin-resistance tuberculosis | Yuanxi Zou | Abstract | |
Lower dose-adjusted concentrations of rifampicin and pyrazinamide in pulmonary versus extra-pulmonary tuberculosis | Gustav Svärdhagen | Abstract | |
A loading dose of clofazimine to optimize treatment in patients with nontuberculous mycobacterial diseases | Ralf Stemkens | Abstract | |
Rapporteur session | Charles Peloquin | ||
DAY 2 Wednesday 2 October | |||
Session 4 Approaches and tools in TB drug development and optimization and in treatment of patients | |||
Chairs: Gerry Davies & Charles Peloquin | |||
Advancing tuberculosis therapy with co-crystals: a comprehensive review | Shagun Gogna | Abstract | |
Using machine learning to expedite area under the curve calculation for PK/PD analysis | Abdullah Alsultan | Abstract | |
Machine-learning time-to-event analysis for prediction of 2-month culture conversion with phase 2a information in tuberculosis drug development | Huifang You | Abstract | |
On our way to personalized therapy: using therapeutic drug monitoring of moxifloxacin for an external pharmacokinetic model evaluation | Emily Behrens | Abstract | |
Evaluation of QT prolongation during bedaquiline treatment using a time-varying tuberculosis-specific correction factor (QTcTBT) | Thanakorn Vongjarudech | Abstract | |
Lectures | Speakers | Presentations | Abstracts | Posters |
DAY 1 Tuesday 26 September | ||||
Session 1 Drugs: clinical and non-clinical pharmacology of TB drugs | ||||
Chairs: Helen McIlleron & Eric Nuermberger | ||||
Invited lecture. New oxazolidinones: lessons learned about sutezolid and delpazolid | Norbert Heinrich | |||
Population pharmacokinetics of sutezolid and its main metabolite to characterize the exposure-response relationship in patients with pulmonary tuberculosis | Simon Koele | Abstract | ||
TBAJ-587 and ERA4TB: a productive clinical development partnership | Almari Conradie | Abstract | ||
Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis | Ralf Stemkens | Abstract | ||
Delpazolid population pharmacokinetics in patients with pulmonary tuberculosis | Isabella van der Feltz | Abstract | ||
Session 2 Patient populations: pharmacological aspects of specific forms of TB | ||||
Chairs: Jerry Nedelman & Ulrika Simonsson | ||||
Invited lecture. Insights on TB meningitis treatment from animal models and advanced imaging techniques | Sanjay Jain | |||
Pharmacokinetics and pharmacodynamics of high-dose isoniazid for the treatment of multidrug-resistant tuberculosis in Indonesia | Vycke Yunivita & Fajri Gafar | Abstract | ||
The association between drug exposure, susceptibility and response and clinical thresholds for pyrazinamide in MDR-TB treatment | Shulan Dong | Abstract | ||
Population pharmacokinetics of rifabutin among co-infected children on lopinavir/ritonavir-based antiretroviral therapy | Manna Semere Gebreyesus | Abstract | ||
Effect of pregnancy on population pharmacokinetics of levofloxacin in South African adults with rifampicin-resistant tuberculosis | Sharon Sawe | Abstract | ||
Session 3 Short presentations & pitches for poster viewing | ||||
Chair: Geraint Davies | ||||
Population pharmacokinetics of macozinone (PBTZ-169) and active metabolites in healthy volunteers after different oral formulations | Budi Octasari Susanto | Abstract | ||
A study of the drug interaction potential of TBAJ-876 on CYP3A4 and P-gp substrates in healthy adults | Jerry Nedelman | Abstract | Poster | |
Pharmacokinetics of levofloxacin during pregnancy and post-partum in persons living with HIV and without HIV and receiving treatment for rifampicin-resistant | Jennifer Hughes | Abstract | Poster | |
Population pharmacokinetic modeling of rifampicin at standard and high doses in adults with tuberculous meningitis | Noha Abdelgawad | Abstract | Poster | |
Population pharmacokinetic modelling of pyrazinamide in plasma and cerebrospinal fluid from HIV-associated tuberculosis meningitis adults | Jose Miguel Calderin | Abstract | Poster | |
Limited sampling strategy and dose evaluation for second-line anti-tuberculosis drugs in patients with type II diabetes mellitus | Jiayi Cao | Abstract | Poster | |
Evaluating two strategies for the design of pediatric pharmacokinetic studies | Yuanxi Zou | Abstract | Poster | |
DAY 2 Wednesday 27 September | ||||
Session 4 The role of consortia in TB drug development | ||||
Chairs: Rob Aarnoutse & Charles Peloquin | ||||
ERA4TB | Santiago Ferrer Bazaga | |||
Unite4TB | Martin Boeree | |||
PAN-TB | Charles Wells | |||
Panel discussion on preselected topics & propositions | Coming Soon | |||
Session 5 Approaches and tools in TB drug development and optimization and in treatment of patients | ||||
Chairs: Susan Swindells & Paolo Denti | ||||
Higher-order combination drug regimens and pharmacodynamic markers of response in a mouse tuberculosis infection model | Michael Lyons | Abstract | ||
Power to identify exposure-response relationships in phase IIa tuberculosis trials with multi-dimensional bacterial load modeling | Simon Koele | Abstract | ||
Development of a PBPK model for TBAJ-876 within the SIMCYP population-based simulator and subsequent evaluation of DDI liability as a victim of CYP3A4 | Ludwig Vincent | Abstract | ||
Drug-drug interaction management of bedaquiline and other medications associated with QT-interval prolongation | David Burger | Abstract | ||
Rifampin dosing and pharmacokinetics from an international TDM service, 2022 | Nicole Maranchick | Abstract | ||
Saliva-based assay to measure the concentration of pyrazinamide using a mobile UV spectrophotometer | Ricky Chen | Abstract | ||
Session 6 Short presentations & pitches for poster viewing | ||||
Chair: Jerry Nedelman | ||||
Co-crystals for tuberculosis | Shagun Gogna | Abstract | Poster | |
4β-hydroxycholesterol-to-cholesterol ratio as an endogenous biomarker in human plasma to determine treatment effects of induction and inhibition of CYP3A4 | Yashara Ryan | Abtract | Poster | |
Population pharmacokinetics of pretomanid in participants of a randomised controlled clinical trial for rifampicin-resistant tuberculosis | Bern-Thomas Nyang'wa | Abstract | Poster | |
Population pharmacokinetics of clofazimine in a randomised controlled clinical trial for rifampicin-resistant tuberculosis | Ilaria Motta | Poster | ||
Physico-chemical properties influencing penetration into saliva: a systematic review | Anh Thi Nguyen | Abstract | Poster | |
Analysis of time to positivity of Mycobacterium tuberculosis in response to treatment for drug susceptible tuberculosis in South African patients | Marie Wijk | Abstract | Poster | |